A new prompt injection attack dubbed "BioShocking" could trick AI-powered browsers into treating real-world risky actions as ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...

Members of the Danville-Pittsylvania Regional Industrial Facility Authority unanimously approved a local performance agreement Monday with Denver-based data center developer and operator Stack ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

For 20 years, he hid his identity behind the nom de plume Foolbert Sturgeon as he chronicled Christ’s encounters with modern-day hypocrites in comic-book form. Frank Stack in a 1986 ...

May 6 (Reuters) - Stack Infrastructure, a data centre firm owned by Blue Owl Capital, is considering its options, including a sale of its Asia operations in a deal valued at more ‌than $30 billion, ...

A new holographic storage technique uses light in three dimensions to dramatically increase how much data can be stored. It encodes information throughout a material using amplitude, phase, and ...

David Pogue is a six-time Emmy winner for his stories on "CBS Sunday Morning," where he's been a correspondent since 2002. Pogue hosts the CBS News podcast "Unsung Science." He's also a New York Times ...

CINCINNATI—Late at night, or when her 18-month-old daughter is napping, Jessica Sharp logs onto Chat GPT and asks it to help her in her fight to stop a data center from being built just steps away ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Recursion (RXRX). The reason why I want to go over this biotech next is because the company ...